President Donald Trump’s Most Favored Nation policies and TrumpRx platform have produced the largest annual drop in U.S. prescription drug prices in over 60 years, the steepest since 1963, according to the administration. The update follows years of price increases across much of the sector which had Americans footing the bill for other nations' usage.

"Without even twisting an arm, without trying to pass a new bill, he [Trump] brought all these players together with TrumpRX to lower the cost of prescription drugs, and he continues to do that because this guy understands leverage. He understands the bully pulpit," Rep. Jimmy Patronis, R-Fla., told Just The News.

TrumpRx has already generated $700 million in patient savings. GLP-1 drugs that previously exceeded $1,000 monthly now start at $149; many other high-cost medications (insulin, inhalers, fertility drugs, cholesterol treatments) have fallen 50–90%. Prescription prices are down 3.9% since Trump took office and have declined every month of 2026.

Nonprescription drugs fell 2.4% and medical-care commodities 2.7% over the past year. 

The Department of Veterans Affairs (VA) also locked in more than $10 billion in pharmaceutical savings this fiscal year, with hundreds of billions projected long-term. The administration states this is the first time a president has actually lowered prescription drug prices.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​

Drug prices were a drag

Prescription drug prices had been climbing for decades leading up to last year.

According to the Bureau of Labor Statistics (BLS) data, prescription drug prices were 5.5 times higher in 2024 than in 1985 and rose roughly three times as fast as overall inflation since 1985. Cardiovascular and insulin/antidiabetic drugs showed some of the steepest increases. Brand-name medications saw repeated list-price increases that often outpaced general inflation, with cumulative rises leaving average annual costs for many therapies several times higher than in the early 2000s. 

Over longer periods, prescription drug prices rose faster than overall consumer prices, contributing to higher out-of-pocket burdens and insurance premiums. Even as net prices after rebates moderated in some recent years, the long-term trajectory left many Americans facing elevated costs for essential treatments until the recent reversal.

Americans footed the bill 

Americans have long paid substantially higher prices for brand-name prescription drugs than patients in other developed countries—often three to four times as much, according to RAND analyses of 2022 data comparing the U.S. to 33 OECD nations. 

Pharmaceutical companies and economic studies maintain that these elevated U.S. prices generate the majority of global revenues required to fund the costly, high-risk research and development of new medicines. 

Other nations’ price controls allow them to pay closer to manufacturing costs, effectively free-riding on American-financed innovation and leaving U.S. patients to shoulder a disproportionate share of the investment that benefits patients worldwide.

Trump’s Most Favored Nation policy directly confronts the long-standing imbalance in which American patients paid far higher prices, often three to four times of those in other developed nations, to fund the bulk of global pharmaceutical research and development. 

By securing voluntary agreements with 17 major drug manufacturers like Eli Lilly, AbbVie and Johnson & Johnson, covering roughly 86% of the branded market, the administration requires U.S. prices to match the lowest levels paid by comparable countries. 

It effectively ends decades of Americans effectively subsidizing cheaper medicines abroad, pressure that had allowed other nations to free-ride on U.S.-financed innovation while patients at home shouldered disproportionate costs for the same drugs.​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​